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ABSTRACT 
  
Nitric oxide (NO) is essential for normal function of the cardiovascular system. This 
study has determined whether chronic administration of L-arginine, the biological 
precursor of NO, attenuates the development of structural and functional changes in 
hearts and blood vessels of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. 
Uninephrectomized rats treated with DOCA (25 mg every 4th day sc) and 1% NaCl in the 
drinking water for 4 wk were treated with L-arginine (5% in food, 3.4 ± 0.3 g·kg body wt–
1·day–1). Changes in cardiovascular structure and function were determined by 
echocardiography, microelectrode studies, histology, and studies in isolated hearts and 
thoracic aortic rings. DOCA-salt hypertensive rats developed hypertension, left 
ventricular hypertrophy with increased left ventricular wall thickness and decreased 
ventricular internal diameter, increased inflammatory cell infiltration, increased 
ventricular interstitial and perivascular collagen deposition, increased passive diastolic 
stiffness, prolonged action potential duration, increased oxidative stress, and inability to 
increase purine efflux in response to an increased workload. L-Arginine markedly 
attenuated or prevented these changes and also normalized the reduced efficacy of 
norepinephrine and acetylcholine in isolated thoracic aortic rings of DOCA-salt 
hypertensive rats. This study suggests that a functional NO deficit in blood vessels and 
heart due to decreased NO synthase activity or increased release of reactive oxygen 
species such as superoxide may be a key change initiating many aspects of the 
cardiovascular impairment observed in DOCA-salt hypertensive rats. These changes can 
be prevented or attenuated by administration of L-arginine. 
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